Targeted treatment for chronic lymphocytic leukemia

References

• MortonLMWangSSDevesaSSLymphoma incidence patterns by WHO subtype in the United States, 1992–2001Blood200610726527616150940
   PubMed Web of Science ®Google Scholar
• HallekMChesonBDCatovskyDGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesBlood20081115446545618216293
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet200737023023917658394
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRHopfingerGFludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood200610788589116219797
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol2005234079408815767648
   PubMed Web of Science ®Google Scholar
• MatutesEParry-JonesNBrito-BabapulleVThe leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patientsLeuk Lymphoma2004452007201515370245
   PubMed Web of Science ®Google Scholar
• KitadaSAndersenJAkarSExpression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponsesBlood199891337933899558396
   PubMed Web of Science ®Google Scholar
• ChiorazziNFM: Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilitiesBlood20111171781179121148333
   PubMed Web of Science ®Google Scholar
• GorgunGRamsayAGHolderriedTAE(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunctionProc Natl Acad Sci U S A20091066250625519332800
   PubMed Web of Science ®Google Scholar
• PleyerLEgleAHartmannTNMolecular and cellular mechanisms of CLL: novel therapeutic approachesNat Rev Clin Oncol2009640541819488076
   PubMed Web of Science ®Google Scholar
• FarahaniMTreweekeATTohCHAutocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cellsLeukemia20051952453015674425
   PubMed Web of Science ®Google Scholar
• DanilovAVDanilovaOVKleinAKMolecular pathogenesis of chronic lymphocytic leukemiaCurr Mol Med2006666567517022736
   PubMed Web of Science ®Google Scholar
• Caligris-CappioFRole of the microenvironment in chronic lymphocytic leukemiaBr J Hematol2003123380388
   Web of Science ®Google Scholar
• Chanan-KhanAAMavromatisBRaiKRA pilot study of genasense (R) (oblimersen sodium, Bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemiaASH Annual Meeting Abstracts20041044827
   Google Scholar
• O’BrienSMClaxtonDFCrumpMPhase I study of obatoclax mesylate (GX15–070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemiaBlood200911329930518931344
   PubMed Web of Science ®Google Scholar
• van DelftMFWeiAHMasonKDThe BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell20061038939917097561
   PubMed Web of Science ®Google Scholar
• BrentjensRJNovel approaches to immunotherapy for B-cell malignanciesCurr Hematol Rep20054647215610662
   PubMedGoogle Scholar
• GhiaPGranzieroLChilosiMChronic B cell malignancies and bone marrow microenvironmentSemin Cancer Biol20021214915512027587
   PubMed Web of Science ®Google Scholar
• GlezerEFerrajoliAReubenJMTreatment with lenalidomide (Revlimid(R)) upregulates CD40 expression on CLL Cells and increases their sensitivity to CD40-mediated cytotoxicity in vitroASH Annual Meeting Abstracts20081123168
   Google Scholar
• HerishanuYVireBLiuDThe role of the microenvironment for CLL proliferation and survival: gene expression profiling of leukemic cells derived from blood, bone marrow and lymph nodes reveals the B-cell receptor and NF {kappa}B as dominant signaling pathwaysASH Annual Meeting Abstracts2008112356
   Google Scholar
• OsterborgAKippsTJMayerJOfatumumab (HuMax-CD20), a Novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trialASH Annual Meeting Abstracts2008112328
   Google Scholar
• Chanan-KhanAAChesonBDLenalidomide for the treatment of B-cell malignanciesJ Clin Oncol2008261544155218285605
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAAPadmanabhanSMillerKCIn vivo evaluation of immunomodulating effects of lenalidomide (L) on tumor cell microenvironment as a possible underlying mechanism of the antitumor effects observed in patients (pts) with chronic lymphocytic leukemia (CLL)ASH Annual Meeting Abstracts20051062975
   Google Scholar
• Chanan-KhanAMillerKCTakeshitaKResults of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)Blood20051063348335216051743
   PubMed Web of Science ®Google Scholar
• GiannopoulosKDmoszynskaAKowalMThalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemiaLeukemia2009231771177819440214
   PubMed Web of Science ®Google Scholar
• KayNEShanafeltTDCallTGN9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemiaLeuk Lymphoma20095058859219373657
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAMillerKCMusialLClinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II studyJ Clin Oncol2006245343534917088571
   PubMed Web of Science ®Google Scholar
• SherTMillerKCLawrenceDEfficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogeneticsLeuk Lymphoma201051858820055660
   PubMed Web of Science ®Google Scholar
• MusialLMillerKCTonelliALow-dose prednisone decreases the severity but not the frequency of lenalidomide associated tumor flare reaction (TFR) in chronic lymphocytic leukemia (CLL) patientsASH Annual Meeting Abstracts20061084987
   Google Scholar
• Chanan-KhanAMillerKCLawrenceDTumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical responseCancer20111172127213521523725
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAACzuczmanMSPadmanabhanSClinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patientsASH Annual Meeting Abstracts20071103108
   Google Scholar
• FerrajoliALeeBNSchletteEJLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood20081115291529718334676
   PubMed Web of Science ®Google Scholar
• FerrajoliAO’BrienSMFaderlSHLenalidomide induces complete and partial responses in patients with relapsed and treatment-refractory chronic lymphocytic leukemia (CLL)ASH Annual Meeting Abstracts2006108305
   Google Scholar
• ChenCPaulHXuWA phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL)ASH Annual Meeting Abstracts200811244
   Google Scholar
• FerrajoliABadouxXCO’BrienSCombination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)ASH Annual Meeting Abstracts2009114206
   Google Scholar
• ChenCIPaulHMarielaPA phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL)ASH Annual Meeting Abstracts20071102042
   Google Scholar
• BadouxXO’BrienSWierdaWGCombination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a phase II trialASH Annual Meeting Abstracts20101162464
   Google Scholar
• OsterborgAOfatumumab, a human CD20 monoclonal antibodyExpert Opin Biol Ther20101043944920109133
   PubMed Web of Science ®Google Scholar
• HuhnDvon SchillingCWilhelmMRituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood2001981326133111520778
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHThomasDARituximab dose- escalation trial in chronic lymphocytic leukemiaJ Clin Oncol2001192165217011304768
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood200310161412393429
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSWenSChemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaJ Clin Oncol2005234070407815767647
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood200811297598018411418
   PubMed Web of Science ®Google Scholar
• HallekMFKFingerle-RowsonGAddition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialLancet20103761164117420888994
   PubMed Web of Science ®Google Scholar
• O’BrienSOsterborgAOfatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemiaClin Lymphoma Myeloma Leuk201010536136821030349
   PubMed Web of Science ®Google Scholar
• CoiffierBLepretreSPedersenLMSafety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 studyBlood20081111094110018003886
   PubMed Web of Science ®Google Scholar
• WierdaWGKippsTJMayerJFinal analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemiaASH Annual Meeting Abstracts2010116921
   Google Scholar
• WierdaWG-KTMayerJHx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaJ Clin Oncol2010281749175520194866
   PubMed Web of Science ®Google Scholar
• WierdaWGKippsTJDurigJOfatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trialASH Annual Meeting Abstracts2009114207
   Google Scholar
• RobakTGA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignanciesCurr Opin Investig Drugs200910588596
   PubMed Web of Science ®Google Scholar
• MorschhauserFCartronGLamyTPhase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemiaASH Annual Meeting Abstracts2009114884
   Google Scholar
• MilaniCCastilloJVeltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpuraCurr Opin Mol Ther20091120020719330725
   PubMed Web of Science ®Google Scholar
• MorschhauserFLeonardJPFayadLHumanized anti- CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II resultsJ Clin Oncol2009273346335319451441
   PubMed Web of Science ®Google Scholar
• GoldenbergDMRossiEASteinRProperties and structure-function relationships of veltuzumab (hA20), a humanized anti- CD20 monoclonal antibodyBlood20091131062107018941114
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood2002993554356111986207
   PubMed Web of Science ®Google Scholar
• OsterborgADyerMJBunjesDPhase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic LeukemiaJ Clin Oncol199715156715749193354
   PubMed Web of Science ®Google Scholar
• NabhanCPattonDGordonLIA pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)Leuk Lymphoma2004452269227315512816
   PubMed Web of Science ®Google Scholar
• HillmenPSkotnickiABRobakTAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clin Oncol2007255616562317984186
   PubMed Web of Science ®Google Scholar
• LozanskiGHeeremaNAFlinnIWAlemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood20041033278328114726385
   PubMed Web of Science ®Google Scholar
• AwanFTLapalombellaRTrottaRCD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibodyBlood20101151204121319965644
   PubMed Web of Science ®Google Scholar
• FurmanRRAndritsosLFlinnIWPhase 1 dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLLASH Annual Meeting Abstracts201011656
   Google Scholar
• AndritsosLFurmanRRFlinnIWA Phase 1 Trial of TRU-016, An Anti-CD37 small modular immunopharmaceutical (SMIPTM) protein in relapsed and refractory CLL: early promising clinical activityASH Annual Meeting Abstracts20091143424
   Google Scholar
• AdvaniRForero-TorresAFurmanRRPhase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphomaJ Clin Oncol2009274371437719636010
   PubMed Web of Science ®Google Scholar
• FurmanRRForero-TorresAShustovAA phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemiaLeuk Lymphoma20105122823520038235
   PubMed Web of Science ®Google Scholar
• RobakTNovel monoclonal antibodies for the treatment of chronic lymphocytic leukemiaCurr Cancer Drug Targets20088215617118336199
   PubMed Web of Science ®Google Scholar
• WoodworthJLeighBRO’BrienSPharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic LeukemiaASH Annual Meeting Abstracts20041044831
   Google Scholar
• ByrdJCCastroJO’BrienSComparison of results from a phase 1/2 study of lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR resultsASH Annual Meeting Abstracts200610832
   Google Scholar
• ByrdJCO’BrienSFlinnISafety and efficacy results from a phase I trial of single-agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemiaASH Annual Meeting Abstracts20041042503
   Google Scholar
• ByrdJCKippsTJFlinnIWPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaBlood201011548949519843887
   PubMed Web of Science ®Google Scholar
• LeMaistreCFSalehMNKuzelTMPhase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2Blood1998913994059427692
   PubMed Web of Science ®Google Scholar
• FrankelAEFlemingDRPowellBLDAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemiaExpert Opin Biol Ther2003317918612718740
   PubMed Web of Science ®Google Scholar
• MorganSJSeymourJFPrinceHMConfirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expressionClin Cancer Res2004103572357515161717
   PubMed Web of Science ®Google Scholar
• GonzalvezFAA: New insights into apoptosis signaling by Apo2L/TRAILOncogene20102947526520531300
   PubMed Web of Science ®Google Scholar
• InoueSMacFarlaneMHarperNHistone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignanciesCell Death Differ200411Suppl 2S19320615608694
   PubMed Web of Science ®Google Scholar
• PlumasJJacobMCChaperotLTumor B cells from non- Hodgkin’s lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosisBlood199891287528859531598
   PubMed Web of Science ®Google Scholar
• MacFarlaneMHarperNSnowdenRTMechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemiaOncogene2002216809681812360407
   PubMed Web of Science ®Google Scholar
• CzuczmanMSMaddipatlaSKnightJIn vitro synergistic antitumor activity by targeting TRAIL-R1 and CD20 antigen by combining HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) and rituximab monoclonal antibody against non-Hodgkin’s lymphoma cells (NHL)ASH Annual Meeting Abstracts20051061475
   Google Scholar
• GhoshalPChittaKVujcicSMapatumumab, a TRAIL receptor 1 agonist antibody, induces apoptosis in bortezomib resistant multiple myelomaASH Annual Meeting Abstracts20091142832
   Google Scholar
• YounesAVoseJMZelenetzADResults of a phase 2 Trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin’s lymphoma (NHL)ASH Annual Meeting Abstracts2005106489
   Google Scholar
• NatoniAMacFarlaneMInoueSTRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signal-ling via TRAIL-R2Br J Haematol200713956857717922877
   PubMed Web of Science ®Google Scholar
• MarksPARichonVMKellyWKHistone deacetylase inhibitors: development as cancer therapyNovartis Found Symp2004259269281 discussion 281–28815171260
   PubMedGoogle Scholar
• KaufmannSHSteensmaDPOn the TRAIL of a new therapy for leukemiaLeukemia20051921952120216224489
   PubMed Web of Science ®Google Scholar
• DrummondDCNobleCOKirpotinDBClinical development of histone deacetylase inhibitors as anticancer agentsAnnu Rev Pharmacol Toxicol20054549552815822187
   PubMed Web of Science ®Google Scholar
• HerishanuYP-GPLiuDThe lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood201111756357420940416
   PubMed Web of Science ®Google Scholar
• FriedbergJWSJSweetenhamJInhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin’s lymphoma and chronic lymphocytic leukemiaBlood20101152578258519965662
   PubMed Web of Science ®Google Scholar
• VeldurthyAPatzMHagistSThe kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genesBlood20081121443145218550857
   PubMed Web of Science ®Google Scholar
• AmreinPCAttarETakvorianTDasatinib has activity in relapsed/refractory chronic lymphocytic leukemia (CLL/SLL), a phase II trialASH Annual Meeting Abstracts20081123162
   Google Scholar
• WangSYangDLippmanMETargeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonistsSemin Oncol20033013314214613034
   PubMed Web of Science ®Google Scholar
• LetaiASorcinelliMDBeardCAntiapoptotic BCL-2 is required for maintenance of a model leukemiaCancer Cell2004624124915380515
   PubMed Web of Science ®Google Scholar
• PatelMPMAPatelPSChanan-KhanAATargeting the Bcl-2Curr Opin Oncol20092151652319730103
   PubMed Web of Science ®Google Scholar
• O’BrienSMooreJOBoydTE5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenJ Clin Oncol2009275208521219738118
   PubMed Web of Science ®Google Scholar
• NguyenMMarcellusRCRoulstonASmall molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisProc Natl Acad Sci U S A2007104195121951718040043
   PubMed Web of Science ®Google Scholar
• BorthakurGO’BrienSRavandi-KashaniFA phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL)ASH Annual Meeting Abstracts20061082654
   Google Scholar
• BalakrishnanKBurgerJAWierdaWGAT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistanceBlood200911314915318836097
   PubMed Web of Science ®Google Scholar
• JamesDCastroJELoriaOPradaCEAguillonRAKippsTJAT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trialJ Clin Oncol2006246605
   PubMed Web of Science ®Google Scholar
• CastroJEOlivierLJRobierAAA Phase II, Open Label Study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaASH Annual Meeting Abstracts20061082838
   Google Scholar
• StolzCHessGHahnelPSTargeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosisBlood20081123312332118689543
   PubMed Web of Science ®Google Scholar
• WilsonWO’ConnerORobertsAWABT-263 activity in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)J Clin Oncol20092715s
   Web of Science ®Google Scholar
• CuniSPerez-AciegoPPerez-ChaconGA sustained activation of PI3 K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cellsLeukemia2004181391140015175625
   PubMed Web of Science ®Google Scholar
• De FriasMIglesias-SerretDCosiallsAMAkt inhibitors induce apoptosis in chronic lymphocytic leukemia cellsHaematologica200994121698170719815839
   PubMed Web of Science ®Google Scholar
• HermanSEGordonALWagnerAJPhosphatidylinositol 3- kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood20101162078208820522708
   PubMed Web of Science ®Google Scholar
• FurmanRRByrdJCBrownJRCAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemiaASH Annual Meeting Abstracts201011655
   Google Scholar
• O’BrienSNew agents in the treatment of CLLHematology Am Soc Hematol Educ Program200845746419074126
   PubMed Web of Science ®Google Scholar
• TrepelJMollapourMGiacconeGTargeting the dynamic HSP90 complex in cancerNat Rev Cancer20101053754920651736
   PubMed Web of Science ®Google Scholar
• KhalilAAKabapyNFDerazSFSmithCHeat shock proteins in oncology: diagnostic biomarkers or therapeutic targets?Biochim Biophys Acta20111816289104Epub ahead of print
   PubMed Web of Science ®Google Scholar
• JonesDTAddisonENorthJMGeldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells’ sensitivity to cytotoxic drugsBlood20041031855186114576064
   PubMed Web of Science ®Google Scholar
• LinKRockliffeNJohnsonGGHsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cellsOncogene2008272445245517982489
   PubMed Web of Science ®Google Scholar
• ChenRKeatingMJGandhiVTranscription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell deathBlood20051062513251915972445
   PubMed Web of Science ®Google Scholar
• ByrdJCLinTSDaltonJTFlavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood200710939940417003373
   PubMed Web of Science ®Google Scholar
• LanasaMCAndritsosLBrownJRInterim analysis of EFC6663, a multicenter phase 2 study of alvocidib (flavopiridol), demonstrates clinical responses among patients with fludarabine refractory CLLASH Annual Meeting Abstracts201011658
   Google Scholar
• TongWGChenRPlunkettWPhase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myelomaJ Clin Oncol201028183015302220479412
   PubMed Web of Science ®Google Scholar
• KnaufWULissichkovTAldaoudAPhase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol2009274378438419652068
   PubMed Web of Science ®Google Scholar
• KnaufWULissichkovTAldaoudABendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III studyASH Annual Meeting Abstracts20071102043
   Google Scholar
• FischerKCramerPStilgenbauerSBendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG)ASH Annual Meeting Abstracts2009114205
   Google Scholar